Rising arterial stiffness with accumulating comorbidities associates with heart failure with preserved ejection fraction
- PMID: 37280726
- PMCID: PMC10375151
- DOI: 10.1002/ehf2.14422
Rising arterial stiffness with accumulating comorbidities associates with heart failure with preserved ejection fraction
Abstract
Aims: Comorbidities play a significant role towards the pathophysiology of heart failure with preserved ejection fraction (HFpEF), characterized by abnormal macrovascular function and altered ventricular-vascular coupling. However, our understanding of the role of comorbidities and arterial stiffness in HFpEF remains incomplete. We hypothesized that HFpEF is preceded by a cumulative rise in arterial stiffness as cardiovascular comorbidities accumulate, beyond that associated with ageing.
Methods and results: Arterial stiffness was assessed using pulse wave velocity (PWV) in five groups: Group A, healthy volunteers (n = 21); Group B, patients with hypertension (n = 21); Group C, hypertension and diabetes mellitus (n = 20); Group D, HFpEF (n = 21); and Group E, HF with reduced ejection fraction (HFrEF) (n = 11). All patients were aged 70 and above. Mean PWV increased from Groups A to D (PWV 10.2, 12.2, 13.0, and 13.7 m/s, respectively) as vascular comorbidities accumulated independent of age, renal function, haemoglobin, obesity (body mass index), smoking status, and hypercholesterolaemia. HFpEF exhibited the highest PWV and HFrEF displayed near-normal levels (13.7 vs. 10 m/s, P = 0.003). PWV was inversely related to peak oxygen consumption (r = -0.304, P = 0.03) and positively correlated with left ventricular filling pressures (E/e') on echocardiography (r = -0.307, P = 0.014).
Conclusions: This study adds further support to the concept of HFpEF as a disease of the vasculature, underlined by an increasing arterial stiffness that is driven by vascular ageing and accumulating vascular comorbidities, for example, hypertension and diabetes. Reflecting a pulsatile arterial afterload associated with diastolic dysfunction and exercise capacity, PWV may provide a clinically relevant tool to identify at-risk intermediate phenotypes (e.g. pre-HFpEF) before overt HFpEF occurs.
Keywords: Arterial stiffness; Heart failure with preserved ejection fraction; Pulse wave velocity; Ventricular-arterial coupling.
© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Conflict of interest statement
None declared.
Figures
Similar articles
-
Heart failure with preserved ejection fraction (HFpEF) pathophysiology study (IDENTIFY-HF): does increased arterial stiffness associate with HFpEF, in addition to ageing and vascular effects of comorbidities? Rationale and design.BMJ Open. 2019 Nov 19;9(11):e027984. doi: 10.1136/bmjopen-2018-027984. BMJ Open. 2019. PMID: 31748285 Free PMC article.
-
Arterial Stiffness and Risk of Overall Heart Failure, Heart Failure With Preserved Ejection Fraction, and Heart Failure With Reduced Ejection Fraction: The Health ABC Study (Health, Aging, and Body Composition).Hypertension. 2017 Feb;69(2):267-274. doi: 10.1161/HYPERTENSIONAHA.116.08327. Epub 2016 Dec 19. Hypertension. 2017. PMID: 27993954 Free PMC article.
-
Association between sleep-disordered breathing and arterial stiffness in heart failure patients with reduced or preserved ejection fraction.ESC Heart Fail. 2018 Jun;5(3):284-291. doi: 10.1002/ehf2.12273. Epub 2018 Feb 20. ESC Heart Fail. 2018. PMID: 29460495 Free PMC article.
-
A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.J Am Coll Cardiol. 2013 Jul 23;62(4):263-71. doi: 10.1016/j.jacc.2013.02.092. Epub 2013 May 15. J Am Coll Cardiol. 2013. PMID: 23684677 Review.
-
Arterial Stiffness and Heart Failure With Preserved Ejection Fraction.J Korean Med Sci. 2024 Jun 17;39(23):e195. doi: 10.3346/jkms.2024.39.e195. J Korean Med Sci. 2024. PMID: 38887204 Free PMC article. Review.
Cited by
-
The association between pulse wave velocity and heart failure: a systematic review and meta-analysis.Front Cardiovasc Med. 2024 Jul 23;11:1435677. doi: 10.3389/fcvm.2024.1435677. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39108667 Free PMC article.
-
Novel Strategies in Diagnosing Heart Failure with Preserved Ejection Fraction: A Comprehensive Literature Review.High Blood Press Cardiovasc Prev. 2024 Mar;31(2):127-140. doi: 10.1007/s40292-024-00629-1. Epub 2024 Mar 15. High Blood Press Cardiovasc Prev. 2024. PMID: 38489152 Free PMC article. Review.
-
Inversion of Left Ventricular Axial Shortening: In Silico Proof of Concept for Treatment of HFpEF.Bioengineering (Basel). 2024 Jul 2;11(7):676. doi: 10.3390/bioengineering11070676. Bioengineering (Basel). 2024. PMID: 39061758 Free PMC article.
-
Sex-related pathophysiological mechanisms may be present before symptoms of HFpEF develop.ESC Heart Fail. 2025 Jun;12(3):2387-2390. doi: 10.1002/ehf2.15228. Epub 2025 Feb 28. ESC Heart Fail. 2025. PMID: 40022454 Free PMC article. Clinical Trial.
-
Association of Cardiac MRI-derived Aortic Stiffness with Early Stages and Progression of Heart Failure with Preserved Ejection Fraction.Radiol Cardiothorac Imaging. 2024 Aug;6(4):e230344. doi: 10.1148/ryct.230344. Radiol Cardiothorac Imaging. 2024. PMID: 39145733 Free PMC article. Clinical Trial.
References
-
- Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Schnaidt S, Zeller C, Schnee JM, Anker SD, for the EMPEROR‐Preserved Trial Study Group . Effect of empagliflozin on worsening heart failure events in patients with heart failure and a preserved ejection fraction: the EMPEROR‐Preserved trial. Circulation. 2021; 144: 1284–1294. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous